2-Oct-2026
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)
TipRanks (Sat, 3-Oct 1:30 PM ET)
Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
TipRanks (Wed, 30-Sep 5:25 AM ET)
Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular Diseases
Globe Newswire (Mon, 14-Sep 6:00 PM ET)
Ascendis Announces Planned $400 Million Share Repurchase Program
Globe Newswire (Mon, 14-Sep 6:00 PM ET)
Globe Newswire (Wed, 9-Sep 4:01 PM ET)
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Globe Newswire (Tue, 8-Sep 4:01 PM ET)
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Globe Newswire (Mon, 7-Sep 7:00 AM ET)
Globe Newswire (Mon, 31-Aug 7:00 AM ET)
Globe Newswire (Tue, 25-Aug 4:01 PM ET)
Globe Newswire (Tue, 18-Aug 8:00 AM ET)
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Ascendis Pharma A/S - Ordinary Share trades on the NASDAQ stock market under the symbol ASND.
As of October 2, 2026, ASND stock price climbed to $227.87 with 629,451 million shares trading.
ASND has a beta of 0.30, meaning it tends to be less sensitive to market movements. ASND has a correlation of 0.01 to the broad based SPY ETF.
ASND has a market cap of $14.99 billion. This is considered a Large Cap stock.
Last quarter Ascendis Pharma A/S - Ordinary Share reported $394 million in Revenue and $1.05 earnings per share. This beat revenue expectation by $41 million and exceeded earnings estimates by $.27.
In the last 3 years, ASND traded as high as $282.15 and as low as $85.29.
The top ETF exchange traded funds that ASND belongs to (by Net Assets): TCAF, IBB, IWP, IWR, IWF.
ASND has underperformed the market in the last year with a price return of +13.4% while the SPY ETF gained +16.1%. ASND has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.0% and -3.7%, respectively, while the SPY returned +3.6% and +1.0%, respectively.
ASND support price is $220.81 and resistance is $233.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASND shares will trade within this expected range on the day.